Press Release

Celsense, Inc Board of Directors Elects Jeffrey S. Friedman M.D., Ph.D., to Board

April 21, 2016 – Pittsburgh, Pennsylvania

The Board of Directors of Celsense, Inc. unanimously elected Jeffrey S. Friedman, M.D., Ph.D., to the Board effective April 21, 2016. Dr. Friedman is the Managing Partner of Friedman Bioventures, a San Diego-based family investment vehicle, and Chair of the Life Science Committee of the San Diego Chapter of Tech Coast Angels, one of the largest Angel Investing organization in the world. Dr. Friedman also serves as Director and Chair of the Research Committee of CurePSP, a nationwide foundation funding research and providing education and support to patients with Progressive Supranuclear Palsy (PSP) and to their families and caregivers. Dr. Friedman previously served on the Boards of Cypher Genomics and Pediatric Biosciences. After receiving his B.S. in Biology at MIT, Dr. Friedman earned his M.D. and Ph.D. in Cancer Biology at Stanford University. He trained in Pediatrics at Boston Children’s Hospital and Pediatric Hematology/Oncology at the Dana Farber Cancer Institute. Dr. Friedman served as an Assistant Professor and Principal Investigator at the Scripps Research Institute in La Jolla, California from 2003 until 2012.

“We are delighted to have Jeff join our Board,” said Paul Kornblith, Chairman of the Board of Celsense.

About Celsense, Inc.
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870

Continue Exploring



Real-Time Results,<br />Faster and More Accurate

Celsense offers products that enable real-time MRI detection of inflammation and cellular therapeutics. The mission of the company is to be the standard for cellular imaging in human health.

Send Us A Message

3 + 14 =

© 2020 Celsense, Inc. All rights reserved.